KROS vs. RCKT, DCPH, AMPH, ARDX, AMRX, MRVI, EWTX, SNDX, NAMS, and DYN
Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Rocket Pharmaceuticals (RCKT), Deciphera Pharmaceuticals (DCPH), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Amneal Pharmaceuticals (AMRX), Maravai LifeSciences (MRVI), Edgewise Therapeutics (EWTX), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Keros Therapeutics (NASDAQ:KROS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Keros Therapeutics currently has a consensus target price of $86.00, suggesting a potential upside of 47.66%. Rocket Pharmaceuticals has a consensus target price of $52.13, suggesting a potential upside of 126.83%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Keros Therapeutics.
Rocket Pharmaceuticals received 331 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 72.18% of users gave Rocket Pharmaceuticals an outperform vote while only 66.67% of users gave Keros Therapeutics an outperform vote.
Keros Therapeutics' return on equity of -46.74% beat Rocket Pharmaceuticals' return on equity.
Keros Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Rocket Pharmaceuticals had 12 more articles in the media than Keros Therapeutics. MarketBeat recorded 20 mentions for Rocket Pharmaceuticals and 8 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.85 beat Rocket Pharmaceuticals' score of 0.43 indicating that Keros Therapeutics is being referred to more favorably in the media.
Keros Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
Summary
Rocket Pharmaceuticals beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Keros Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Keros Therapeutics Competitors List
Related Companies and Tools
